Olink® Explore HT

Discover the ultimate tool for multiplex protein analysis of precious samples. This white paper provides an overview of how Olink's proximity extension assay (PEA) technology has been used to measure 10s to 1000s of protein biomarkers from minute volumes of precious samples across major research areas, while delivering high data quality and robust performance.

Looking to innovate your approach to drug development? Don’t be left behind!

With this free infographic, find out how a reverse translation approach can be utilized to produce a wealth of actionable insights to eliminate drug failure, speed up your time-to-market, and reduce R&D costs.

Olink® Explore HT is the next-generation solution for high-throughput proteomics. In this application note, Olink Proteomics showcases how the rigorous testing and validation process for each individual biomarker assay featured on Olink Explore HT, reflects Olink’s commitment to quality, rigor and transparency.

Olink® protein panels are widely employed for biomarker discovery, enabling the precise measurement of multiple proteins across numerous samples simultaneously. In this case study, learn how Olink® Explore HT was used to screen circulating protein biomarkers of ovarian cancer, leading to the identification of a high-performance diagnostic protein signature.

In this engaging infographic, explore how top biomarker discovery methods in proteomics, Olink’s Proximity Extension Assay (PEA™) and liquid chromatography-mass spectrometry (LC-MS), compare in profiling proteins in plasma and serum.

Proteomic analysis identified fazirsiran treatment-responsive protein biomarkers in patients with alpha-1 antitrypsin deficiency-associated liver disease.

Alpha-1 antitrypsin deficiency (AATD) is a rare genetic disease that causes low levels of the protein alpha-1 antitrypsin (AAT) in the blood, mainly affecting the lungs and liver. When someone has the Pi*ZZ genotype, the AAT protein is misfolded (called Z-AAT), leading to harmful aggregates in the liver and reduced protection in the lungs. This misfolding can cause liver damage, inflammation, and fibrosis due to the build up of these harmful proteins. Currently, no pharmacological treatments for AATD-associated liver disease (AATD-LD) exist.

Dr. Jen-Chieh Chuang, Director and Translational Biomarker Lead for Liver Diseases, will describe the proteomic analysis that identified treatment-responsive protein biomarkers for AATD-associated liver disease, enabling treatment to become a possibility for those affected.

Key learning objectives

• Understand how new proteomics tools are enabling the discovery of biomarkers for possible therapies for diseases that currently do not exist
• Discover how these tools can help you to understand the mechanism of action of disease states to better understand what target would be best for therapies

Who should attend?

• Anyone working in drug development 
• Anyone working in a disease area where therapies or treatments are lacking
• Anyone working in the area of precision medicine

Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.

Hear from Professor Guillaume Paré from McMaster University, as he discusses the critical shift away from the traditional 'one biomarker, one disease' paradigm. He advocates for a more dynamic view of biomarkers, particularly focusing on protein signatures that can support better disease understanding and therapy development.

Olink is paving the way with its PEA technology to support the analysis of 5–5400+ proteins simultaneously. By working with an Olink Certified Service Provider such as CRLB-GMEL headed by Professor Guillaume Paré, investigators are enabled to redefine the boundaries of medical research and gain unique insights into disease biology, aiding the identification of new therapeutic targets and biomarkers.